

**GYNAECOLOGY SUSPECTED CANCER REFERRAL FORM**

Date of GP decision to refer: [Click here to enter a date.](#)  
EMAIL REFERRAL TO: [twowwgpreferrals.enh-tr@nhs.net](mailto:twowwgpreferrals.enh-tr@nhs.net)

PATIENT DETAILS – <b>Must provide current telephone number.</b>	GP DETAILS
Last name: _____ First name: _____ Gender: M <input type="checkbox"/> F <input type="checkbox"/> DOB: _____ NHS No: _____ Address: _____  Tel (mobile/daytime): _____ Tel (evening): _____ Patient agrees to telephone message being left? Y <input type="checkbox"/> N <input type="checkbox"/> Email: _____ Interpreter required? Y <input type="checkbox"/> Language/Hearing: _____ Learning difficulties? Y <input type="checkbox"/> Mental capacity assessment required? Y <input type="checkbox"/> Known safeguarding concerns? Y <input type="checkbox"/> Mobility requirements (unable climb on/off bed)? Y <input type="checkbox"/>	GP name: _____ Practice Code: _____ Address: _____  TEL: _____ FAX: _____ Practice email: _____ Practice direct access telephone/GP mobile – for Consultant use only: _____
INVESTIGATIONS IN SUPPORT OF REFERRAL	
Pelvic ultrasound normal? Y <input type="checkbox"/> N <input type="checkbox"/> Ca125 <input type="checkbox"/> Result: _____ Date of last cervical smear: _____ Result: _____	
HORMONAL STATUS	
<input type="checkbox"/> Premenopausal <input type="checkbox"/> Postmenopausal (>1yr since LMP) <input type="checkbox"/> On HRT                      Type of HRT: _____ <input type="checkbox"/> Hysterectomy <input type="checkbox"/> Hormonal contraceptive    Please specify: _____	
PATIENT MEDICAL HISTORY	
<i>Existing conditions &amp; risk factors (inc. smoking status):</i> <input type="checkbox"/> Current smoker <input type="checkbox"/> Referred to stop-smoking service  <i>History of cancer:</i> Breast <input type="checkbox"/> Bowel <input type="checkbox"/> Other (specify) _____  <i>Existing conditions &amp; risk factors (more space overleaf):</i>  <i>Current medication (attach list &amp; indications):</i> Tamoxifen/Raloxifene etc <span style="float:right">Y <input type="checkbox"/></span> Anticoagulants/Antiplatelets <span style="float:right">Y <input type="checkbox"/></span> Immunosuppressants <span style="float:right">Y <input type="checkbox"/></span> Diabetic <span style="float:right">Y <input type="checkbox"/></span> Allergies <span style="float:right">Y <input type="checkbox"/></span>  <i>WHO Patient Performance status (see key below)</i> <input type="checkbox"/> 0 <input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4	
ADDITIONAL INFORMATION	
DISCUSSIONS WITH PATIENT PRIOR TO REFERRAL	
Cancer needs to be excluded	<input type="checkbox"/>
Patient given referral information leaflet	<input type="checkbox"/>
Date(s) unavailable in next 14 days: _____	
SYMPTOMS (SUSPECTED CANCER REFERRAL)	
OVARIAN CANCER - <b>please send Ca125 and USS results</b>	
<input type="checkbox"/> Ovarian mass consistent with cancer on USS and/or report recommends two week referral (see notes overleaf) <b>Postmenopausal or aged 50 years or over</b> <input type="checkbox"/> Palpable pelvic mass, not obviously fibroid, GI or renal tumour <input type="checkbox"/> Raised CA125 with abnormal USS <input type="checkbox"/> Unexplained persistent or rising CA125 with normal USS	
ENDOMETRIAL CANCER - <b>please perform pelvic &amp; speculum exam</b>	
<b>Premenopausal and aged over 45</b> <input type="checkbox"/> Persistent intermenstrual/irregular bleeding not attributable to contraception or polyp and/or not responsive to HRT or cyclical progesterones. <input type="checkbox"/> Suspicious vaginal bleeding (sudden change/irregular/heavy) <b>Postmenopausal</b> <input type="checkbox"/> Bleeding (after 12 months of amenorrhoea) <input type="checkbox"/> Recurrent bleeding (after previous investigation) <input type="checkbox"/> in women who have not had hysteroscopy <input type="checkbox"/> despite oestrogen treatment following normal hysteroscopy and biopsy <input type="checkbox"/> Thickened endometrium as an incidental finding without PMB <input type="checkbox"/> ETT (endometrial thickness) > 10mm <input type="checkbox"/> USS recommends 2ww referral due to ETT 5-10mm with suspicious features	
CERVICAL CANCER – <b>please perform pelvic &amp; speculum exam</b>	
Suspicious lesion that looks like tumour on: <input type="checkbox"/> cervix or <input type="checkbox"/> vagina <input type="checkbox"/> Postcoital bleeding for > 4 weeks AND negative Chlamydia test	
VULVAL CANCER	
<input type="checkbox"/> Visible vulval tumour: exophytic ‘cauliflower’ or ?malignant ulcer <input type="checkbox"/> Unexplained vulval bleeding <input type="checkbox"/> Persistent vulval pain/itching	
GP SUSPICION NOT FULFILLING SPECIFIC CRITERIA	
<input type="checkbox"/> Ovarian <input type="checkbox"/> Endometrial <input type="checkbox"/> Cervical <input type="checkbox"/> Vulval/Vaginal <b>Please specify concern in referral letter</b>	

**\*PLEASE ATTACH A PATIENT SUMMARY INCLUDING: REFERRAL LETTER, INVESTIGATION RESULTS, PMH, CURRENT MEDICATIONS LIST AND INDICATIONS**

**If you have not received acknowledgement within 48 hours (Mon-Fri) contact 2ww supervisor on 01438 285206**

## WHO PATIENT PERFORMANCE STATUS KEY

<b>0</b>	Fully active, able to carry on all pre-disease performance without restriction
<b>1</b>	Restricted in physically strenuous activity but ambulatory and able to carry out light/sedentary work, e.g. house or office work.
<b>2</b>	Ambulatory and capable of self-care, but unable to carry out work activities. Up and active > 50% of waking hours.
<b>3</b>	Capable of only limited self-care. Confined to bed or chair >50% of waking hours.
<b>4</b>	Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair.

## FOR HOSPITAL USE ONLY

Date referral received:	--/--/----	If 1 <sup>st</sup> appointment date not accepted, give reason/s:
1 <sup>st</sup> appointment date offered:	--/--/----	
2 <sup>nd</sup> appointment date offered:	--/--/----	

## GUIDANCE ON REFERRAL CRITERIA

The monthly conversion rate of two week wait referral to a diagnosis of a gynaecological cancer fluctuates between 4% and 14% and yet many cancers are still referred acutely or to other specialities. This guidance draws on the latest evidence, the experience of the multidisciplinary team and latest NICE guidelines. It is intended to help GPs navigate the referral criteria so that resources can be concentrated on those patients most at risk, thereby reducing delays to diagnosis and avoiding unnecessary anxiety to women who do not merit a two week wait referral.

### OVARIAN CANCER

*Please follow NICE CG122 only for women after 50 or after menopause*

*CA125 should not be the first test below 50 years*

*Referral with single raised CA125 result is not indicated unless scan is abnormal*

*USS is recommended as well as CA125 even if normal*

#### Postmenopausal

1. New diagnoses of IBS (recent change in bowel habit) are unusual in women over 50. Ovarian cancer should always be suspected (NICE 122) & CA125 tested. USS should be arranged if CA125 is raised.
2. Unilocular ovarian cysts (no septations or solid areas) are likely to be benign and can be referred non urgently **providing CA125 is not elevated.**
3. All other ovarian/uterine masses on USS or palpable pelvic masses in postmenopausal women should be referred on a two week wait.
4. High CA125 may be caused by an ovarian cancer despite a normal USS although there are other causes such as diverticular disease or IBD. Consider urgent referral for patients with significantly raised or rising CA125.

#### Premenopausal

1. Two week referral should be made if USS report suggests cancer.
2. "Complex" masses described as haemorrhagic, dermoid, endometrioma or fibroid do not suggest cancer and should be referred routinely as should any other "Significant Abnormality" alerts that do not state likelihood of cancer. USS reports should clarify this.
3. An elevated CA125 is not diagnostic of ovarian cancer. Many benign conditions which cause peritoneal inflammation will raise CA125 including cyclical change, endometriosis, haemorrhagic cysts, infection, diverticular and inflammatory bowel disease, ascites from liver or cardiac disease.etc.

### ENDOMETRIAL CANCER

*Pelvic examination must be performed before referral to exclude cervical cancer (NICE)*

*Endometrial measurements before menopause have no value in diagnosing cancer*

#### Postmenopausal

1. All cases of postmenopausal bleeding need to be investigated.
2. Consider stopping HRT first and referring if bleeding persists.
3. Pelvic ultrasound (TVS) with endometrial thickness (ETT) <5mm is reassuring.
4. Women with persistent bleeding or abnormal ETT need biopsy.
5. Women with continued or recurrent bleeding should be re-referred for hysteroscopy if not previously done, as should women with persistent bleeding despite reassuring hysteroscopy and treatment with oestrogen.

#### Premenopausal

1. About 20% of endometrial cancers are diagnosed in women under 55 years and are very rare in women under 45 years. Delayed diagnosis does not seem to be a major problem in premenopausal women.
2. Algorithms to refer "at risk women" are difficult to develop or validate but investigation is based upon biopsy triggered by symptoms and not on USS findings.
3. Menorrhagia is not a reason for two week referral. Abnormal bleeding may be treated empirically.

4. Sudden, recent and significantly abnormal bleeding patterns merit two week referral as does non-response to hormonal treatment.

***Incidental finding without PMB***

1. Incidental finding of “thickened” endometrium >10 mm requires investigation.
2. Investigation is required for ETT 5-10mm only if advised because of additional suspicious features.

**CERVICAL CANCER**

1. Women with smear suggesting invasion will have automatic two week direct referral to colposcopy.
2. All women with postcoital bleeding for >4 weeks should undergo pelvic examination in primary care, be screened for chlamydia and have cervical smear if they do not have an in-date smear.
3. Two week referral is not indicated for cervical polyps.

**VULVAL CANCER**

1. Most vulval cancers are obvious with raised or ulcerated tumour and may be sore or itchy or bleed.
2. Vulval ulceration (unless obvious herpes) is regarded as malignant until proven otherwise.
3. Smooth vulval lumps deep to the vulval skin do not suggest cancer and should be referred routinely, or urgently if recent growth raises suspicion.